Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$20.07M, compared with -$27.54M a year earlier. Trailing-twelve-month operating income was -$85.86M.
Context
- Operating income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 4 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +19.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$20.07M+3.4% QoQ
- Last fiscal yearDec 2025
- -$93.33M+19.5% YoY
- LTMMar 2026
- -$85.86M+21.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.1% | +100.0% | +72.9 pp |
| 1 year | +19.5% | +100.0% | +80.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (93.33M) USD
- Year-over-year change
- +19.5%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (93.33M) | +19.5% |
| FY2024 | 2024-12-31 | (115.95M) | +11.6% |
| FY2023 | 2023-12-31 | (131.19M) | -4.4% |
| FY2022 | 2022-12-31 | (125.62M) | -72.5% |
| FY2021 | 2021-12-31 | (72.81M) | — |
Operating Income vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 operating income of -$85.86M is the 6th highest of the 11 companies compared; the peer median is -$85M.
- Its year-over-year change of +21.8% is the 3rd highest of 11, against a peer median of +17.8%.
- Operating income amounts to 38159.1% of revenue for TNYA, versus a peer median of 561.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$59.23M | +7.8% | — | — | |
| LTM Mar 2026 | -$60.38M | +40.9% | — | 87.2% | |
| LTM Mar 2026 | -$64.12M | +18.5% | — | — | |
| LTM Mar 2026 | -$80.77M | +17.1% | — | 286.2% | |
| LTM Mar 2026 | -$84.14M | +39.9% | — | 503.2% | |
| LTM Mar 2026 | -$85.86M | +21.8% | — | 38159.1% | |
| LTM Mar 2026 | -$85.87M | +19.6% | — | 619.6% | |
| LTM Mar 2026 | -$92.75M | -33.3% | — | 637.9% | |
| LTM Mar 2026 | -$113.89M | -2.6% | — | 5649.2% | |
| LTM Mar 2026 | -$127.42M | -25.2% | — | 349.2% | |
| LTM Mar 2026 | -$131.71M | +19.5% | — | 1175.7% | |
| Peer median (excluding TNYA) | -$85M | +17.8% | — | 561.4% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| Weighted Avg Shares | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Weighted Avg Shares (Diluted) | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.